Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kyowa Kirin Korea Co., Ltd.
Age
19–64
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
≥ 19 years old, and ≤ 64 years old, and
Female patients with breast cancer receiving chemotherapy recently covered under national health insurance (only chemotherapy regimens in the table below), and
Patients with neutropenic events (febrile neutropenia or grade 4 neutropenia) in any previous cycle that did not use G-CSF for the prevention of neutropenia
You may not be if
Patients with any of the followings are excluded.
Patients with a history of allergic reactions to E-coli derived proteins, human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim
Uses for off-label indications such as chronic myelogenous leukemia, myelodysplastic syndrome
Clareo Health | An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)
